Novo Nordisk A/S: Tresiba(R) (insulin degludec) and Ryzodeg(R)

Novo Nordisk A/S: Tresiba(R) (insulin degludec) and Ryzodeg(R)
(insulin degludec/insulin aspart) receive positive opinions from the
European regulatory authorities 
BAGSVAERD, DENMARK -- (Marketwire) -- 10/19/12 --  
Company Announcement No 66 / 2012: 
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that: 

(i)  the releases contained herein are protected by copyright and
     other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
     originality of the information contained therein.

Source: Novo Nordisk A/S via Thomson Reuters ONE [HUG#1650358] 
Further information: 
Mike Rulis
Tel: (+45) 3079 3573 
Kasper Roseeuw Poulsen
Tel: (+45) 4442 4303 
Frank Daniel Mersebach
Tel: (+45) 4442 0604 
Lars Borup Jacobsen
Tel: (+45) 3075 3479 
In North America: 
Ambre Morley
Tel: (+1) 609 216 5240 
Jannick Lindegaard
Tel: (+1) 609 786 4575
Press spacebar to pause and continue. Press esc to stop.